QUOTE AND NEWS
StreetInsider.com  Jul 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/DexCom+%28DXCM%29+Enters+Settlement+with+Abbott+Diabetes+Care/9640903.html for the full story.
Forbes  Jun 16  Comment 
In trading on Monday, the iShares U.S. Medical Devices ETF (IHI) is outperforming other ETFs, up about 1.5% on the day.  Components of that ETF showing particular strength include shares of Covidien (COV), up about 19.3% and shares of Dexcom...
TheStreet.com  Jun 5  Comment 
NEW YORK (TheStreet) -- Good day, traders! Today's top pick are DexCom , Iamgold and Conn's . 1. First, let's look at the medical device company, DexCom. It focuses on the design, development and commercialization of continuous glucose...
StreetInsider.com  Jun 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/DexCom%2C+Inc.+%28DXCM%29+G4+PLATINUM+Professional+CGM+Receives+FDA+Approval/9550267.html for the full story.
TheStreet.com  May 16  Comment 
NEW YORK (TheStreet) -- TheStreet's Jim Cramer says DexCom , a company that makes glucose monitoring systems, should be on investors' radars. DexCom's devices, which do not require finger pricking, have a disruptive technology that caused the...
TheStreet.com  May 16  Comment 
NEW YORK (Real Money) -- Let's use DexCom (DXCM) as a poster boy for what's both right and wrong with this market. Here's a company with disruptive technology -- a device to monitor glucose remotely with no finger pricking -- that's pretty much...
TheStreet.com  May 16  Comment 
Search Jim Cramer's "Mad Money" trading recommendations using our exclusive "Mad Money" Stock Screener. NEW YORK (TheStreet) -- Here are some of the hot stocks Jim Cramer talked about on Thursday's Mad Money on CNBC: CVE data by...
SeekingAlpha  May 2  Comment 
DexCom, Inc. (DXCM) Q1 2014 Results Earnings Conference Call May 1, 2014 4:30 PM ET Executives Terry Gregg - Chief Executive Officer Kevin Sayer - President and COO Jess Roper - Chief Financial Officer Steve Pacelli - Executive...
SeekingAlpha  May 1  Comment 
The following audio is from a conference call that will begin on May 01, 2014 at 16:30 PM ET. The audio will stream live while the call is active, and can be replayed upon its completion. Listen now Complete Story »
Market Intelligence Center  Apr 16  Comment 
MarketIntelligenceCenter.com's patented trade-picking algorithms have identified an attractive covered-call trade on DexCom (DXCM). Look at the Sep. '14 $30.00 covered call for a net debit in the $28.66 area. This trade has a duration of 157...




 

DXCM, based in San Diego, California, is an emerging medical device company focused on the design and development of continuous glucose monitoring(CGM) systems for people with diabetes. The company is currently engaged in the development of two continuous glucose-monitoring systems: a short-term system with a sensor that can be inserted by a patient, and a long-term system with a sensor that can be implanted by a physician. A key element of DXCM's monitoring system technology is the continuous measure of patient's blood glucose level and the real-time transmission of that information to a small cell phone-sized receiver. DXCM's monitoring systems aim to provide real-time continuous blood glucose values, trend data and alert patients to assist in managing their blood glucose levels. In contrast, currently available self-monitoring systems use disposable test strips to test blood sampled at discrete points in time.

History & Products

The company was founded in 1999 and listed on April 19, 2005 through the issue of 4,700,000 shares of common stock, raising $52.5M. DXCM has eight issued U.S. patents expiring between 2006 and 2021, and 60 additional U.S. patent applications pending. In 1Q06 DXCM received Food and Drug Administration (FDA) approval for its STS Continuous Glucose Monitoring System, which was subsequently launched nationally on March 28, 2006.

The SEVEN System

The SEVEN System is presented as an alternative to the "finger-stick" method of glucose monitoring. By using continuous glucose monitoring(CGM) individuals who would normally monitor their levels via infrequent testing throughout the day can track their glucose levels as a trend from moment to moment. The SEVEN System is made up of three components: the sensor, the transmitter and the receiver; and are designed to be small, unobtrusive, and lightweight. Comparison with competitive products can be viewed below in "Competition."

DexCom Data Manager 2

Designed to analyze downloaded data from the SEVEN receiver, DexCom's diabetes management software provides users to track their trends and progress over time. This includes the ability to plot CGM values across several days and overlaid on the target range for comprehensive lifestyle evaluation.

Business & Financials

Trends & Forces

Competition

[1] DexCom SEVEN System Freestyle Navigator Guardian RT
Hypo-Safety-Alarm Yes, less than or equal to 55 mg/dL (Cannot be turned off) No No
Sensor life Up to 7 days Up to 5 days Up to 3 days
Sensor warm-up time after calibration 2 hours 10 hours 2 hours
Average lag time 5 minutes 14 minutes Not documented
Calibration (minimum requirement) Twice a day 4 times over 5 days Twice a day
Introducer needle size (diameter) .5mm (26 gauge) .72mm (21 gauge) .65mm (22 gauge)
Transmitter weight 6.8 grams 13.6 grams 7.1 grams
Transmitter power Built in and lasts for life of Transmitter (1.5 Years) Battery cell must be replaced Rechargeable
Receiver power Rechargeable Battery lasts about 30 days Battery lasts about 2 to 4 weeks
Calibration restrictions Accepts calibration values between 40-400 mg/dL Accepts calibration values between 60-300 mg/dL. No calibrations during or around meals, exercise, or while sleeping. Accepts calibration values between 40-400 mg/dL. No calibrations with changing glucose values.

WikiData

References

  1. DexCom Product Comparison
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki